HER2-POSITIVE BREAST CANCER

This early-phase study tests a new type of vaccine made from a patient's own immune cells. The vaccine is given directly into the spinal fluid to target breast cancer that has spread to the lining of the brain and spinal cord. The main goal is to find the safest dose and see if i…

This study tests a combination of chemotherapy (Taxotere) and a targeted drug (trastuzumab) given before surgery to shrink tumors in Nigerian women with HER2-positive breast cancer. The main goal is to see how many women have no cancer cells left in the breast or lymph nodes at t…

This study tests whether a newer drug, margetuximab, works better than the standard trastuzumab when combined with chemotherapy and pertuzumab before surgery for stage II-III HER2-positive breast cancer. About 174 participants will receive one of the two combinations. The main go…

This study tests a new drug called BL-M07D1, alone or with other medications, as a first treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The goal is to see if the drug shrinks tumors and how safe it is. About 83 adults aged 18 to …

This early-stage study tests a new drug called ELVN-002 combined with trastuzumab (and sometimes chemotherapy) in people with advanced HER2-positive cancers, including breast, colorectal, and gastric cancers. The main goal is to find a safe dose and check for side effects. About …

This study looks at whether some women with HER2-positive early breast cancer can be treated with a combination of two targeted drugs (pertuzumab and trastuzumab) without needing chemotherapy. The researchers are selecting patients whose tumors are strongly driven by the HER2 pat…

This study tests a new drug (TVB-2640) combined with standard treatments for people with HER2+ breast cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors or slow the disease. About 17 adults with advanced brea…

This early-phase trial is testing an experimental drug called ZN-A-1041, taken as a capsule, for people with advanced HER2-positive solid tumors (including breast cancer) that have spread or come back after prior treatment. The study includes people with or without brain metastas…

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard stereotactic radiation can better control brain metastases that are at high risk of coming back after radiation alone. About 134 adults with brain tumors from cancers like melanoma, lung, breast, or …

This study tests a two-step treatment for people with HER2-positive breast cancer that has spread or cannot be removed. First, patients receive a strong drug called trastuzumab deruxtecan. Then, they switch to a maintenance combination of two other drugs (trastuzumab and pertuzum…

This study tests whether adding the drug tucatinib to standard treatment (trastuzumab and pertuzumab) helps keep HER2-positive breast cancer from getting worse in people whose cancer has spread. About 650 participants will receive either tucatinib or a placebo pill, and neither t…

This study looks at whether people with HER2-positive metastatic breast cancer who have done very well on anti-HER2 therapy (cancer controlled for 3+ years) can safely stop that treatment. Researchers will monitor those who stop versus those who continue to see if the cancer stay…

This study tests a less intense chemotherapy combination for people with early-stage HER2-positive breast cancer. The goal is to see if a milder regimen (paclitaxel, trastuzumab, and pertuzumab) can clear the cancer before surgery as effectively as the standard stronger regimen, …

This study aimed to see if giving less chemotherapy before surgery, followed by targeted therapy based on how the tumor responded, could work well for people with early-stage HER2-positive breast cancer. It planned to enroll women aged 18 and older with tumors at least 2 cm or ly…

This study tests a combination of two targeted drugs (trastuzumab and pertuzumab) plus hormone therapy given after surgery for people with stage I hormone receptor-positive, HER2-positive breast cancer. The goal is to see if this approach helps prevent the cancer from coming back…

This study looks at whether women and men aged 40+ with early-stage, low-risk HER2-positive breast cancer can safely skip radiation after breast-conserving surgery if they have already received chemotherapy and HER2-targeted therapy. About 1,300 participants will be randomly assi…

This study looks at whether adding pegfilgrastim (a drug that increases white blood cells) to standard chemotherapy and trastuzumab can help the immune system better attack HER2-positive breast cancer. About 90 women with early-stage, operable breast cancer will be randomly assig…

This phase 3 trial compares a new drug called A166 to the standard drug T-DM1 in people with HER2-positive breast cancer that has spread or cannot be removed. Participants must have already tried trastuzumab and a taxane chemotherapy. The main goal is to see if A166 delays cancer…

This study tests whether adding tucatinib (a targeted pill) to standard T-DM1 therapy works better than T-DM1 alone for people with advanced HER2-positive breast cancer that has spread or cannot be removed surgically. About 466 participants will randomly receive either tucatinib …

This phase 3 study tests whether a new drug, DB-1303, works better than the current standard T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. About 228 adults who have already tried trastuzumab and a taxane will be randomly assign…

This early-phase study tests a new treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The treatment involves taking the patient's own immune cells, modifying them to recognize and attack HER2-positive cancer cells,…

This study tests whether a special PET scan can predict if the drug T-DM1 will work in people with advanced HER2-positive breast cancer that has spread. Ten women with metastatic breast cancer received a radioactive tracer to see where the drug goes in the body. The goal is to he…

This study tests two different vaccines in people who had HER-2 positive breast cancer and still had cancer cells after initial treatment. The goal is to see if the vaccines are safe and can help prevent the cancer from coming back. Participants receive a series of vaccine shots …

This study looks at whether a cardiopulmonary exercise test (CPET) can help predict heart and lung function in women with HER2-positive breast cancer who have mild heart problems from their treatment. About 23 women will do a special exercise test to measure oxygen use. The goal …

This study looks at how the area around a tumor changes during chemotherapy in people with HER2-positive breast cancer. Researchers will take samples before, during, and after treatment in 30 patients who are getting chemo before surgery. The goal is to understand these changes b…

This study aimed to see if a new type of imaging (PET/MRI) could detect how well targeted therapy was working in people with stage IV HER2+ breast cancer. It planned to compare scans taken before and during treatment. However, the study was withdrawn before any participants were …